Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for EIK1004 in Solid tumors with and without brain metastases. The expected timing is based on the latest available company guidance and may change.
05/11/26:- CNS-penetrant PARP1 inhibitor EIK1004 Ph1/2 ongoing in solid tumors with/without brain metastases; dose escalation completion expected 2H 2026. 07/20/26:- ESMO 2026 to present initial Phase 1/2 results for EIK1004. 08/13/26:- Initial EIK1004 Ph1/2 data will be presented October 23, 2026; the trial is ongoing.
Verification
Confirm timing and program details against the company announcement or filing.